Dupilumab Effective in Young Children with Eczema, Regardless of Type 2 Inflammatory Comorbidities
Young children with moderate-to-severe atopic dermatitis (AD) can benefit from dupilumab treatment, regardless of whether they have type 2 inflammatory comorbidities, such as asthma, allergic rhinitis (AR), or food allergies (FAs), according to a new post hoc analysis of the LIBERTY AD PRESCHOOL trial published in Advances in Therapy.
The study analyzed data from children aged 6 months to 5 years who received dupilumab or placebo over 16 weeks. Results showed that significantly more children treated with dupilumab achieved clear or almost clear skin (Investigator’s Global Assessment score of 0/1) and at least a 75% improvement in the Eczema Area and Severity Index, whether they had asthma or AR (P< 0.05). Among children with FAs, dupilumab significantly improved skin clearance (P = 0.0007), with a similar trend observed in those without FAs (P = 0.06).
In addition to skin improvements, dupilumab significantly reduced itch severity. More children on dupilumab achieved a ≥4-point reduction in itch scores compared to placebo, regardless of their AR or FA status (P-values ranging from 0.0001 to 0.008). Even among children with asthma, dupilumab showed a numerical benefit in itch reduction, though the difference was not statistically significant (P = 0.6).
“Dupilumab treatment improves AD signs and symptoms in children aged 6 months to 5 years with and without type 2 comorbidities such as asthma, AR, and FAs,” concluded the study authors.
Reference
Boguniewicz M, Sher LD, Paller AS, et al. Dupilumab is efficacious in young children with atopic dermatitis regardless of type 2 comorbidities. Adv Ther. 2024;41(12):4601-4616. doi:10.1007/s12325-024-02998-4
© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of The Dermatologist or HMP Global, their employees, and affiliates.
The APP Institute is dedicated to educating and informing advanced practice providers on clinical topics and practical issues to support the profession and improve the quality of patient care across the spectrum of dermatology.
The APP Institute | Dermatology is designed for Advanced Practice Providers who specialize in Dermatology, to further their education and increase their knowledge to achieve better patient outcomes. Explore cutting-edge research, innovative treatment options, and new therapeutic methods, while remaining focused on the fundamental principles and terminology associated with Dermatology. Engage year-round with the Dermatology Learning Network to access clinical insights, interactive features, research news updates, accredited continuing education programs, and more.
